In this binational cohort study including predominantly patients with type 2 diabetes, use of GLP-1 receptor agonists compared with SGLT2 inhibitors was not associated with an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders. This evidence concerns the gene SLC5A2 and depressive disorder.